Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations

Immuneering Corporation announced that the US FDA has cleared its Investigational New Drug application for IMM-6-415, paving the way for the company to initiate a Phase I/IIa clinical trial of this oral, twice-daily small molecule, in development for the treatment of advanced RAF or RAS mutant solid tumors.